Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: video (3)

Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler Korman
investorpress clippingsvideoscience
Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler KormanApril 15, 2025
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
talentpress releaseinvestorvideo
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025
Fox Business: Interview with Chief Market Strategist, Lou Basenese
investorpress clippingsvideo
Fox Business: Interview with Chief Market Strategist, Lou BaseneseMarch 17, 2025
Fox Business: Interview with CEO Michael Heltzen
heltzeninvestorpress clippingsvideo
Fox Business: Interview with CEO Michael HeltzenMarch 3, 2025
Watch eXoZymes' Nasdaq closing bell ceremony
heltzeninvestorvideo
Watch eXoZymes' Nasdaq closing bell ceremonyFebruary 20, 2025
ARCHIVE: Creating value for partners through exozyme biosolutions
investorvideo
ARCHIVE: Creating value for partners through exozyme biosolutionsFebruary 12, 2025
ARCHIVE: The difference between enzymes and exozymes: Explaining our tech
investorvideoARCHIVE
ARCHIVE: The difference between enzymes and exozymes: Explaining our techFebruary 12, 2025
ARCHIVE: Vision: What's the potential impact of exozymes?
investorvideoARCHIVE
ARCHIVE: Vision: What's the potential impact of exozymes?February 12, 2025
ARCHIVE: eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymes
investorvideoARCHIVE
ARCHIVE: eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymesFebruary 12, 2025
ARCHIVE: Looking at the rest of 2025 - part 4 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Looking at the rest of 2025 - part 4 of a fireside chat about InvizyneFebruary 11, 2025
Previous page
Page 3 of 4
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark